✨ Free AI Report
Ocata Therapeutics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Ocata Therapeutics
Company Research

Ocata Therapeutics: Business Overview, Financials & Competitive Analysis

Ocata Therapeutics scores 6/10 on the AskCyborg Cyborg Score (Solid). Ocata's deep expertise in pluripotent stem cell therapy and position within Astellas provides credibility and resources, but commercial success depends on regulatory approvals and market penetration in ophthalmology. As a subsidiary of a major pharmaceutical company with established clinical programs and strong IP protections, Ocata has solid fundamentals but limited.

What is Ocata Therapeutics's industry? Ocata Therapeutics (ocatatherapeutics.com) operates in Regenerative Medicine. AskCyborg classifies Ocata Therapeutics under Regenerative Medicine in its company registry.

Ocata Therapeutics is a subsidiary of Astellas Pharma focused on regenerative ophthalmology and stem cell therapies for retinal diseases. The company develops cell therapy treatments targeting macular degenerative con...

6/ 10Solid

Cyborg Score thesis

Ocata's deep expertise in pluripotent stem cell therapy and position within Astellas provides credibility and resources, but...

Read the full analyst-debate transcript →
Industry Regenerative Medicine
2 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Ocata Therapeutics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Ocata Therapeutics

AskCyborg analysts argue the bull and bear cases for Ocata Therapeutics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Ocata Therapeutics OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Ocata Therapeutics Overview

Pro stress-test →

Ocata Therapeutics is a subsidiary of Astellas Pharma focused on regenerative ophthalmology and stem cell therapies for retinal diseases. The company develops cell therapy treatments targeting macular degenerative conditions including Dry AMD, Stargardt disease, and myopic macular degeneration.

Strategic Profile

Pro stress-test →

Ocata leverages proprietary pluripotent stem cell platforms (human embryonic stem cells and induced pluripotent stem cells) to address significant unmet medical needs in ophthalmology. Following its acquisition by Astellas in (February 2016) for $379 million, the company operates as Astellas' regenerative ophthalmology innovation center with clinical-stage pipeline programs.

Competitive Landscape

Pro stress-test →

Ocata competes in the regenerative ophthalmology and cell therapy space with other companies developing stem cell treatments for retinal diseases. Key competitive areas include pluripotent stem cell platforms and clinical-stage cell therapies for macular degeneration and related ocular disorders.

Industry Context

Ocata Therapeutics operates in Regenerative Medicine.

Key facts

Founded: 1994 · Headquarters: Marlborough, US

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Ocata Therapeutics.

  • Core focus on regenerative ophthalmology with multiple programs in clinical development for serious macular degeneration conditions
  • Strong intellectual property portfolio protecting pluripotent stem cell platforms across multiple formats and formulations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2016Acquired by Astellas Pharma for $379 million
Get alerted when Ocata Therapeutics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Regenerative Medicine Advanced TherapiesCell and gene therapy approaches for ophthalmology→Cell Therapy ProgramsRegenerative medicine and cell-based treatments→

Compare Ocata Therapeutics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Ocata Therapeutics operates in Regenerative Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Regenerative Medicine research →
NEW · MCP server

Ask your AI assistant about Ocata Therapeutics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Ocata Therapeutics and its top competitor on Cyborg Score”
“What did Ocata Therapeutics do this quarter?”
“Is Ocata Therapeutics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Ocata Therapeutics do?+
Ocata Therapeutics is a subsidiary of Astellas Pharma focused on regenerative ophthalmology and stem cell therapies for retinal diseases. The company develops cell therapy treatments targeting macular degenerative con...
What is Ocata Therapeutics's Cyborg Score?+
Ocata Therapeutics has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Ocata Therapeutics's main competitors?+
Named competitors include Regenerative Medicine Advanced Therapies, Cell Therapy Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Ocata Therapeutics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Ocata Therapeutics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Ocata Therapeutics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Regenerative Medicine research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Humacyte, Inc.6TELA Bio, Inc.5Organogenesis Holdings Inc.4Longeveron Inc.